

Allelic Polymorphisms of *KIRs* and *HLAs* Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML



Hiroshi Ureshino¹, Takero Shindo^{1,2}, Hiroto Kojima³, Yasushi Kusunoki³, Yuki Miyazaki³, Hidenori Tanaka³, Hiroh Saji³, Atsushi Kawaguchi⁴, and Shinya Kimura¹

Abstract

Response to tyrosine kinase inhibitors (TKIs) is variable in chronic myeloid leukemia (CML), and elevated natural killer (NK) cells during TKI therapy are positively correlated with superior outcomes. NK cell function involves interactions of their killer immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I on target cells, and the avidity of KIR–HLA interactions depends on the combination of *KIR* and *HLA* alleles. We hypothesized that *KIR* and *HLA* polymorphisms may influence response to TKIs. *KIR* and *HLA* allele genotyping was performed by next-generation sequencing for 76 CML cases, and association with clinical outcome was analyzed. Second-generation TKIs as first-line therapy and patients' sex (female) were strongly associated with achievement of complete molecular response (CMR: MR^{4.0}) after 2 years ($P < 0.001$ and $P = 0.002$, respectively). After adjustment for these two characteristics, several *KIR* alleles remained associ-

ated with achievement of MR^{4.0}: *KIR2DL4**005/011 or *008 (HR = 1.797, $P = 0.032$); *KIR2DS4**003 or *007/010 (HR = 3.348, $P < 0.001$); *KIR3DL1**005 (HR = 2.746, $P = 0.003$); and *KIR3DL2**009 or *010 [HR = 1.980 (1.109–3.524), $P = 0.021$]. Strong linkage among these alleles exists, implying that they comprise favorable *KIR* allele haplotypes. Allelic polymorphisms of *KIR3DL1* and HLA-B determine their differential avidity into strong/weak or no interaction. Patients carrying noninteracting *KIR3DL1* and HLA-B allele pairs achieved better outcomes than those with strongly interacting pairs, and *KIR3DL1**005 associated with a positive outcome among patients with weak-interacting pairs. Thus, *KIR3DL1**005 and its associated haplotypes associated with superior TKI therapeutic effects. The combinations of these *KIR* and *HLA* alleles may correlate with potent NK cell immunity against CML. *Cancer Immunol Res*; 6(6); 745–54. ©2018 AACR.

Introduction

Tyrosine kinase inhibitors (TKIs) can suppress chronic myeloid leukemia (CML) cells that harbor *BCR-ABL1* mutations (Philadelphia chromosome) in an ATP-competitive manner, and have dramatically improved long-term outcomes of CML patients (1). However, it remains unclear whether TKIs enable treatment-free remission (TFR) in CML. Because TKIs do not kill leukemia stem cells (2), TKI treatment was considered to be required for all through life, even after achievement of deep molecular remission (3- to 4-log reduction in *BCR-ABL1* transcripts; ref. 3). However, long-term TKI therapy can cause late-onset adverse events, includ-

ing renal insufficiency, pleural effusion, cardiovascular events, and can also result in high costs (4, 5). Hence, several clinical trials have investigated the feasibility of discontinuing TKIs (6–9). Overall, these trials have demonstrated that approximately a half of patients who achieve deep molecular remission experience TFR.

Given that TKIs do not directly kill leukemia stem cells (2) but achieve TFR, TKIs may trigger cytotoxicity against CML cells indirectly. Several lines of evidence demonstrate that TKIs enhance antitumor immunity by suppressing regulatory T cells (10, 11). Treatment with interferons, allogeneic hematopoietic stem cell transplantation (allo-HSCT), and donor lymphocyte infusion can suppress CML and have definite positive clinical impacts (12). Antitumor immunity can be carried out by T cells, B cells, and natural killer (NK) cells and, interestingly, increased numbers of NK cells are positively associated with TFR in several TKI discontinuation trials (7, 13, 14). Collectively, TKIs may not only directly suppress the activity of *BCR-ABL1* but also enhance antitumor NK cell immunity against CML. However, responses to TKIs vary among patients, and not all cases achieve TFR. The factors that determine the effects of TKIs in individual patients have yet to be fully elucidated.

NK cells are a facet of innate immunity and can damage tumor cells and pathogens via secretion of cytotoxic granules or initiating antibody-dependent cellular cytotoxicity (15). The balance of activating and inhibitory signals received through NK cell receptors determines their cytotoxic activity (16). In particular, killer immunoglobulin-like receptors (KIRs) play pivotal roles in the

¹Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan. ²Department of Hematology/Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan. ³HLA Foundation Laboratory, Kyoto, Japan. ⁴Center for Comprehensive Community Medicine, Faculty of Medicine, Saga University, Saga, Japan.

Note: Supplementary data for this article are available at Cancer Immunology Research Online (<http://cancerimmunolres.aacrjournals.org/>).

Corresponding Author: Takero Shindo, Department of Hematology/Oncology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogo-in, Sakyo-ku, Kyoto 606-8507, Japan. Phone: 81-75-751-4964; Fax: 81-75-751-4963; E-mail: takeros@kuhp.kyoto-u.ac.jp

doi: 10.1158/2326-6066.CIR-17-0462

©2018 American Association for Cancer Research.

recognition of human leukocyte antigen (HLA) class I molecules on target cells (17). KIRs are classified into activating and inhibitory KIRs depending on their transducing intracellular signals (18). Humans typically carry 9 to 15 activating or inhibitory *KIR* genes, combinations of which are classified into haplotypes A and B. Currently, haplotype B is defined by the presence of one or more of the following genes: *KIR2DS1/2/3/5*, *KIR3DS1*, and *KIR2DL2/5*. Haplotype A is defined by the absence of all these genes (19). Interaction between inhibitory KIRs and their cognate HLA is also crucial in the mediation of NK cell responsiveness during differentiation, referred to as "licensing" or "education" (20). KIRs also exhibit extensive allelic polymorphisms, which can confer functional diversity (21).

Polymorphic *KIR* genotypes have clinical impacts in viral infections, autoimmune disorders, and malignancies (17, 22). Regarding hematologic malignancies, antibodies targeting inhibitory KIRs enhance antilymphoma activity (23). Several reports have investigated the clinical impacts of specific KIRs. Although *KIR2DS1* positivity is associated with a better outcome in allo-HSCT recipients (24, 25), TKI-treated CML patients lacking *KIR2DS1* achieve superior outcomes (26, 27). Assuming that each KIR has cognate immunologic functions, it may be expected that investigations of different diseases would reach similar conclusions. However, studies investigating the associations between disease outcome and KIR molecules have reached inconsistent conclusions regarding the immunomodulatory impacts of KIRs, possibly because of insufficient knowledge of KIR functions.

Next-generation sequencing can fully define *KIR* allelic polymorphisms, which have been associated with infections, autoimmune disorders, and several cancers (28). In particular, *KIR3DL1* exhibits abundant allelic polymorphisms and is associated with three differential expression levels: high (*KIR3DL1-h*), low (*KIR3DL1-l*), and null (*KIR3DL1-n*; refs. 29, 30). Among HLA-Bw4 epitopes, an amino acid dimorphism at position 80 (isoleucine (80I) and threonine (80T)) defines differential inhibition of KIR3DL1 activity (31). Therefore, the combination of *KIR3DL1* alleles and HLA-B epitopes may determine the avidity of each specific interaction and, consequently, the magnitude of NK cell immune responses (21, 32–34). For example, *KIR3DL1-h* alleles appear to be suppressive (33), and alleles encoding HLA-Bw4-80I epitopes result in stronger ligands for KIR3DL1 than HLA-Bw4-80T epitope–encoding alleles (31, 35). Although allelic combinations of KIR and HLA with high avidity correlate with protection against HIV infection (36), such pairs are also associated with worse outcome in neuroblastoma patients treated with monoclonal anti-GD2 (37) and higher leukemia relapse rates after allo-HSCT (38). Strong interactions between inhibitory KIRs and their ligands, the allelic combinations of KIR and HLA with high avidity, may be associated with vigorous inhibition of NK cell immunity, whereas weak or no interactions are related to elevated NK cell function (37, 38). In the meantime, strong interactions may also be associated with high levels of licensing of NK cell immunity.

We hypothesized that polymorphisms of *KIR* and *HLA* genes correlated with the therapeutic effects of TKIs in CML. In particular, we focused on the avidity of interactions between KIR3DL1 and HLA-B epitopes that may define the magnitude of NK cell cytotoxicity. We performed allelic genotyping of activating and inhibitory *KIRs* and *HLAs* in 76 CML patients by next-generation sequencing. Activating *KIRs* (*KIR2DS1*, *KIR2DS2*, *KIR2DS3*, *KIR2DS4*, *KIR2DS5*, and *KIR3DS1*) and

inhibitory *KIRs* (*KIR2DL1*, *KIR2DL2*, *KIR2DL3*, *KIR3DL1*, *KIR3DL2*, and *KIR2DL5*) were genotyped. In particular, three activating *KIRs* (*KIR2DS1*, *KIR2DS4*, and *KIR3DS1*) and six inhibitory *KIRs* (*KIR2DL1*, *KIR2DL2*, *KIR2DL3*, *KIR2DL4*, *KIR3DL1*, and *KIR3DL2*) with known ligands were genotyped. We then analyzed associations of genotypes, as well as their combinations, with patient clinical outcomes.

Methods and Materials

Patients

Patients with Philadelphia chromosome–positive CML in chronic phase (CML-CP; $n = 76$) treated at Saga University Hospital between April 2002 and September 2016 with TKIs (imatinib, dasatinib, nilotinib, or bosutinib) as first-line therapy were investigated for distributions of *KIR* gene frequencies, *KIR* and *HLA* genotypes (including allele typing), and KIR–HLA combinations. Diagnosis of CML was according to the World Health Organization classification of myeloid neoplasms and acute leukemia (39). Baseline patient characteristics were obtained from the hospital records and included general characteristics (age, sex), hematologic data (complete blood count, blast count, percentage of eosinophils, and basophils), molecular diagnosis (*BCR-ABL* transcript level), and spleen size. All the patients were treated with only TKIs, and none received allo-HSCT. Written informed consent was obtained from all the patients before registration, in accordance with the Declaration of Helsinki. The study was approved by the institutional review board of Saga University, enabling gene-panel sequencing and data sharing with qualified investigators. The study was registered in the University Hospital Medical Information Network Clinical Trial Registry System (UMIN-CTR, ID: R000020356).

Real-time quantitative PCR

The therapeutic effects of TKIs were evaluated based on peripheral blood *BCR-ABL* mRNA expression. Patients' RNA was purified from their whole blood by QIAamp RNA Blood Mini Kit (QIAGEN). *BCR-ABL* mRNA expression was measured by real-time quantitative (RQ)-PCR adjusted to the international reporting scale (IS) by ODK-1201 kit (Otsuka Pharmaceutical Co.) or by the transcription-mediated amplification (TMA) method using DNA probe FR Amp-CML kit (Fujirebio Inc.). Major molecular response (MMR) was defined as a 3-log reduction ($MR^{3.0}$) of RQ-PCR (IS) or *BCR-ABL* transcript expression of <50 copies/0.5 μ g RNA using the TMA method. We also defined complete molecular response (CMR) as a 4-log reduction ($MR^{4.0}$) of RQ-PCR (IS), which was equivalent to undetectable *BCR-ABL* transcript expression using the TMA method.

Genotyping of KIR and HLA

Patients' DNA was purified from their whole blood with QIAamp DNA Blood Midi kit (QIAGEN) and stored at -20°C . Allelic genotyping of *HLA* and *KIR* genes was performed using DNA samples by next-generation sequencing (NGS) using Illumina MiSeq technology. For genotyping, commercially available typing kits, HLA version 3.0 IGS kit (Cisco Genetics Inc.) for HLA genotyping and KIR IGS kit version 1.0 (Cisco Genetics Inc.) for KIR genotyping were used according to the manufacturer's instructions (40). Briefly, DNA samples were subjected to amplification PCR and pooling, enzymatic cleanup, barcoding, barcode

pooling, magnetic bead-based size selection, and finally quantification at MiSeq platform. Regions targeted for multiplex short-range PCR were exons 1 to 7 of *HLA-A*, *B*, and *C*; exons 1 to 4 of *HLA-DRB1*, *-DRB3*, *-DRB4*, *-DRB5*, *-DQA1*, *-DQB1*, *-DPA1*, and *-DPB1*; and exons 3, 4, 5, and 9 of *KIR* genes. Gene copy numbers of one or two were categorized as "positive," while samples with a copy number of zero were classified as "blank." *KIR2DL4-3DL1/3DS1-2DS4-3DL2* haplotypes were estimated at the allele level, and their frequencies were determined using Haplo.stats software (version 1.7.7) operated in R.

Antibodies and flow cytometry

Patients' peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation using lymphocyte separation medium (MP Biomedical) and were subjected to flow cytometric analyses. Cells (1×10^6) suspended in phosphate-buffered saline with 5% fetal bovine serum (FBS; Sigma-Aldrich), 2 mmol/L EDTA, and 0.05% NaN₃ were stained with the following monoclonal antibodies for 20 minutes at room temperature in dark: anti-CD3-FITC (OKT3; TONBO Biosciences), anti-CD56-PE-Cy7 (HCD56; BioLegend), anti-CD107a-Pacific Blue (H4A3; BioLegend), anti-CD16-APC-Cy7 (3G8; BD Biosciences), and anti-CD158e1-APC (DX9; BD Biosciences). For staining IFN γ , surface antigen-stained cells were fixed for 30 minutes and then permeabilized and also intracellularly stained for anti-IFN γ -V450 (B27; BD Biosciences) for 30 minutes with respective buffers (Thermo Fisher Scientific). Stained samples were assessed using a FACSVerser cytometer (BD Biosciences) and analyzed with FlowJo software (TreeStar).

Assessment of NK cell activity

The activation status of NK cells was evaluated by staining for CD107a degranulation and intracellular IFN γ secretion of CD3⁺CD16⁺CD56⁺ NK cells using flow cytometry. PBMCs (5×10^5) from patients were cocultured with K562 cells, which lack HLA class I expression. The effector-target ratio was adjusted to 10 to 1 in RPMI 1640 medium supplemented with 10% FBS (41). Anti-CD107a-Pacific Blue was added, followed by a 6-hour incubation, during which brefeldin A (GolgiPlug; BioLegend) and monensin (GolgiStop; BioLegend) were added after 1 hour. Prior to staining for intracellular IFN γ , the cells were fixed and permea-

bilized with the described buffers (Thermo Fisher Scientific) after staining surface antigens.

The K562 cell was purchased from RIKEN, and short tandem repeat DNA profiling analyses using PCR authenticated that it was the same as those registered in the ATCC (CCL-243, K-562), the Japanese Collection of Research Biosources (JCRB) Cell Bank (JCRB0019, K-562; JCRB1002, K562/ADM; and JCRB1402, K562-Luc), the RIKEN BRC Cell Bank (RCB0027, K562; RCB1197, P2UR/K-562; RCB0474, K562/MTX-2; RCB1898, K562/Adr; and RCB2111, K562/Vin), and in Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ; ACC-10, K-562), by comparison with the JCRB database. K562 was used within 2 months after thawing or 25 passages, and *mycoplasma* infection was regularly checked.

Statistical analyses

Cumulative incidence probabilities were calculated using the Kaplan-Meier method. All curve comparisons were completed using a log-rank test for time to achievement of MR^{4.0}. Crude and covariate adjusted hazard ratios (HRs) and their 95% confidence intervals (95% CIs) were computed using the Cox proportional hazards model. In these estimates, sex and first-line treatment were selected as clinical covariates. Two-tailed *P* values < 0.05 were considered statistically significant. All the statistical analyses were performed using R Version 3.3.1 downloaded from <http://cran.ism.ac.jp>.

Results

Characteristics and *KIR* alleles of CML patients

A total of 76 patients with CML-CP who received TKI treatment were investigated in this study. The median follow-up time was 4.9 years (range, 0.7–14.6 years), and the median age of the total cohort was 62.5 years (range, 21–88 years). Forty-seven patients were male and 29 were female, and 39, 24, 10, and 3 patients had low, intermediate, high, and unknown Sokal scores, respectively. All patients received the first-generation TKI imatinib (*n* = 30) or the second-generation TKIs dasatinib or nilotinib (*n* = 46) as first-line treatment. After two years of treatment, MR^{4.0} was achieved by 48% of patients (Fig. 1A). Second-line treatment with second-generation TKIs was required for 36 patients, due to adverse events




Figure 1.

Cumulative incidences of MR^{4.0} at 2 years according to first-line therapy and sex. **A**, Cumulative incidence of MR^{4.0} (%MR^{4.0}) achievement is shown for all patients. Forty-eight percent of patients achieved MR^{4.0} at 2 years. **B** and **C**, Cumulative incidence of MR^{4.0} achievement according to first-line treatment (**B**) and sex (**C**) are presented. **B**, Solid line, patients treated with second-generation TKIs as first-line therapy; dashed line, patients treated with imatinib (*P* < 0.001). **C**, Solid line, female patients; dashed line, male patients (*P* < 0.039). Number of patient indicated in **A–C**. All curve comparisons were completed using log-rank tests for time to achievement of MR^{4.0}, and *P* < 0.05 were considered statistically significant.

Ureshino et al.

Table 1. Patient characteristics

Sex (%)	
Male	47 (61.8)
Female	29 (38.2)
Age, mean years (range)	62.5 (21–88)
Age ≥65 years, number (%)	22 (28.9)
Age at diagnosis, mean years (range)	55.5 (17–83)
Complete blood count at diagnosis, mean value (range)	
White cell count × 10 ⁹ /L	24 (8.2–290)
Hemoglobin g/L	13.6 (5.6–16.8)
Platelet count × 10 ⁹ /L	495 (106–2032)
Sokal risk group, number (%)	
Low	39 (51.3)
Intermediate	24 (31.6)
High	10 (13.2)
Unknown	3 (3.9)
First-line TKI, number (%)	
Imatinib	30 (39.5)
Dasatinib	35 (46.1)
Nilotinib	11 (14.5)
Second-line TKI, number (%)	
Dasatinib	24 (31.6)
Nilotinib	9 (11.8)
Bosutinib	3 (3.9)
Third-line TKI, number (%)	
Dasatinib	5 (6.6)
Nilotinib	2 (2.6)
Median follow-up, years (range)	4.9 (0.7–14.6)

(AEs) or suboptimal responses. Seven patients needed third-line TKI treatment. The clinical characteristics of patients are summarized in Table 1.

NGS of DNA extracted from patient peripheral blood samples was performed to determine their *KIR* alleles (Table 2). *KIR2DL4*, *KIR2DS4*, *KIR3DL1/3DS1*, and *KIR3DL2* exhibited diverse polymorphisms, consistent with a previous report of *KIR* alleles in the Japanese population (33).

First-line treatment and female sex are associated with achievement of MR^{4.0}

First-line treatment with second-generation TKIs and the patients' sex (female) were associated with achievement of MR^{4.0} at 2 years (second-generation TKIs: HR = 7.305; 95% CI = 3.377–15.803, $P < 0.001$; female sex: HR = 1.709; 95% CI = 1.028–2.842, $P = 0.039$; Table 3, Fig. 1B and C). Because only these two characteristics were statistically significant in multivariate analysis adjustment for covariates, we analyzed other potentially prognostic factors after adjustment for these variables. Sokal scores segregated patients into low ($n = 39$), intermediate ($n = 24$), and high ($n = 10$) groups. Scores were not associated with achievement of MR^{4.0} in univariate analyses. However, adjustment for sex (female) and first-line treatment revealed that high Sokal scores were associated with achievement of MR^{4.0}, compared with low or intermediate scores (low vs. high: HR = 0.462; 95% CI = 0.218–0.982, $P = 0.045$; intermediate vs. high: HR = 0.384; 95% CI = 0.168–0.881, $P = 0.024$; low vs. intermediate: HR = 1.033; 95% CI = 0.582–1.833, $P = 0.913$; Table 3).

No single *KIR* gene was associated with achievement of MR^{4.0}

We next analyzed associations between each *KIR* gene and achievement of MR^{4.0}. Because almost all patients carried at least one of *KIR2DL1*, *KIR2DL3*, *KIR2DS4*, or *KIR3DL1* genes, patients were segregated into two subgroups: (i) two allelic types of these genes and (ii) zero or one allele. Due to almost all patients having

Table 2. Genotyped *KIR* alleles in CML patients; duplicated allele were not observed

	Number	Frequency
<i>KIR2DL2/3</i>		
3*001	136	89.5%
2*003	11	7.2%
3*023	2	1.3%
2*001	1	0.7%
3*009	1	0.7%
3*019	1	0.7%
<i>KIR2DL1</i>		
*003	128	84.2%
*002	12	7.9%
*004	1	0.7%
Blank	11	7.2%
<i>KIR2DL4</i>		
*001	76	50.0%
*005/011	42	27.6%
*006	24	15.8%
*008	9	5.9%
Blank	1	0.7%
<i>KIR3DL1/S1</i>		
*015	69	45.4%
*007	24	15.8%
3DS1*013	23	15.1%
*005	15	9.9%
*001	9	5.9%
*020	5	3.3%
3DS1*085	3	2.0%
*029	1	0.7%
*038	1	0.7%
3DS1*078	1	0.7%
Blank	1	0.7%
<i>KIR2DS1</i>		
*002	26	17.1%
*002/003	2	1.3%
Blank	124	81.6%
<i>KIR2DS4</i>		
*001	69	45.4%
*004	15	9.9%
*004-variant	9	5.9%
*003	14	9.2%
*007/010	9	5.9%
*014/016	6	3.9%
*015	2	1.3%
Blank	28	18.4%
<i>KIR3DL2</i>		
*002	70	46.1%
*007	23	15.1%
*008	20	13.2%
*010	18	11.8%
*009	9	5.9%
*001/*049	3	2.0%
*015	3	2.0%
*016	2	1.3%
*021	2	1.3%
*024	1	0.7%
*027	1	0.7%

NOTE: As *KIR2DL2/DL3* and *KIR3DL1/DS1* alleles are shared within the same gene, they are shown in the same category *KIR2DL2/3* and *KIR3DL1/S1*, respectively. *KIR2DS4**004 variant is the allele that changed aspartic acid (D) to valine (V) at codon 57 in *004.

two alleles for *KIR2DL4*, *KIR3DL2*, and *KIR3DL3* genes, these *KIRs* were excluded from further analyses. Consequently, we analyzed associations with alleles for *KIR2DL1*, *KIR2DL2*, *KIR2DL3*, *KIR2DL5*, *KIR2DS1*, *KIR2DS2*, *KIR2DS3*, *KIR2DS4*, *KIR2DS5*, and *KIR3DL1*. None of these *KIRs* were associated with achievement of MR^{4.0} (Table 3).

Table 3. Statistical analyses of achievement of MR^{4.0}

	Univariate analysis			First-line therapy and sex adjusted	
	n (%)	HR (95% CI)	P	HR (95% CI)	P
<i>KIR2DL1</i> (2 vs. 1)	65 (85.5)	0.859 (0.405–1.821)	0.692	1.268 (0.585–2.748)	0.548
<i>KIR2DL2</i> (1 vs. 0)	12 (15.8)	1.243 (0.606–2.546)	0.553	1.115 (0.534–2.330)	0.772
<i>KIR2DL3</i> (2 vs. 1)	64 (84.2)	0.805 (0.393–1.648)	0.553	1.115 (0.534–2.330)	0.772
<i>KIR2DL5</i> (1, 2 vs. 0)	29 (37.8)	1.026 (0.983–1.071)	0.236	1.02 (0.976–1.066)	0.38
<i>KIR2DS1</i> (1, 2 vs. 0)	27 (35.5)	1.023 (0.980–1.068)	0.295	1.015 (0.971–1.061)	0.517
<i>KIR2DS2</i> (1 vs. 0)	12 (15.8)	1.243 (0.607–2.546)	0.553	0.897 (0.429–1.874)	0.772
<i>KIR2DS3</i> (1, 2 vs. 0)	8 (10.5)	1.003 (0.939–1.071)	0.93	1.024 (0.958–1.095)	0.478
<i>KIR2DS4</i> (2 vs. 0, 1)	49 (64.5)	0.966 (0.906–1.031)	0.295	0.978 (0.916–1.045)	0.517
<i>KIR2DS5</i> (1 vs. 0)	20 (26.3)	1.430 (0.823–2.483)	0.205	1.151 (0.652–2.034)	0.627
<i>KIR3DL1</i> (2 vs. 0, 1)	49 (64.5)	0.966 (0.906–1.031)	0.295	0.978 (0.916–1.045)	0.517
<i>KIR2DL1</i> positive/ <i>HLA-C2</i> positive	10 (13.2)	2.521 (1.209–5.258)	0.014	1.915 (0.890–4.122)	0.097
<i>KIR2DL2</i> positive/ <i>HLA-C1</i> positive	12 (15.8)	1.243 (0.607–2.546)	0.553	1.115 (0.534–2.330)	0.772
<i>KIR3DL1</i> positive/ <i>HLA-Bw</i> positive	64 (84.2)	0.539 (0.276–1.055)	0.071	0.725 (0.368–1.430)	0.353
<i>KIR2DL4</i> *005/011 or *008	40 (52.6)	1.942 (1.160–3.250)	0.012	1.797 (1.052–3.067)	0.032
<i>KIR2DS4</i> *003 or *007/010	20 (26.3)	3.878 (2.125–7.075)	<0.001	3.348 (1.773–6.323)	<0.001
<i>KIR3DL1</i> *005	14 (18.4)	3.634 (1.884–7.013)	<0.001	2.746 (1.403–5.376)	0.003
<i>KIR3DL2</i> *009 or *010	22 (28.9)	1.864 (1.067–3.258)	0.029	1.980 (1.109–3.524)	0.021
Activating KIR positive	35 (46.1)	1.383 (0.830–2.304)	0.214	1.094 (0.636–1.881)	0.745
KIR haplotype A/A	41 (53.9)	0.723 (0.434–1.205)	0.214	0.914 (0.532–1.572)	0.745
Female sex	29 (37.8)	1.709 (1.028–2.842)	0.039	N/A	
Age 65 years and over	22 (28.9)	1.262 (0.718–2.219)	0.419	1.180 (0.651–2.138)	0.586
Sokal score low vs. high	Low: 39 (51.3%)	0.635 (0.306–1.316)	0.222	0.462 (0.218–0.982)	0.045
Sokal score intermediate vs. high	Int: 24 (31.6%)	0.594 (0.271–1.302)	0.193	0.384 (0.168–0.881)	0.024
Sokal score low vs. intermediate	High: 10 (13.2%)	1.001 (0.566–1.770)	0.997	1.033 (0.582–1.833)	0.913
First-line dasatinib or nilotinib	46 (60.5)	7.305 (3.377–15.803)	<0.001	N/A	

KIR haplotypes, activating KIRs, their matching ligands and MR^{4.0}

KIR haplotype A consists of several inhibitory KIRs and one activating KIR (*KIR2DS4*), and 41 patients (53.9%) were homozygous for this haplotype. All but one patient carried the *KIR2DS4* gene, and 35 patients (46.1%) had activating KIRs other than *KIR2DS4* (Table 3). Homozygosity for KIR haplotype A and the presence of activating KIR genes other than *KIR2DS4* were not associated with achievement of MR^{4.0} (Fig. 2A and Table 3; haplotype A: HR = 0.723, 95% CI = 0.434–1.205, $P = 0.214$; presence of activating KIR genes other than *KIR2DS4*: HR = 1.383, 95% CI = 0.830–2.304, $P = 0.214$).

We also investigated the impacts of functional activating KIR and HLA genotype combinations. We focused on the pairs of *KIR2DS1/S3* and *HLA-C2*, and *KIR2DS2* and *HLA-C1*, which have been well-investigated activating KIR/HLA pairs. No association between the presence of these combinations with achievement of MR^{4.0} was found (present: $n = 24$; absent: $n = 52$; HR = 0.918, 95% CI = 0.566–1.67, $P = 0.958$; Fig. 2B).


Inhibitory KIR genes and their matching ligands are not associated with MR^{4.0}

Combinations of inhibitory KIRs and their cognate ligands are important in modulation of NK cell cytotoxicity during their development (42). Therefore, we investigated whether inhibitory KIRs and their matching ligands were associated with achievement of MR^{4.0}. Because all the patients were positive for *HLA-C1* and its matched ligand gene *KIR2DL3*, this pair was excluded from further analyses. No association between the presence of a single functional combination of an inhibitory KIR–HLA genotype was found (*KIR2DL1/HLA-C2*, *KIR2DL2/HLA-C1*, or *KIR3DL1/HLA-Bw4*) with achievement of MR^{4.0} (Table 3). We then analyzed whether carrying multiple functional KIR–HLA genotype combinations was associated with achievement of MR^{4.0} (43). Patients carried between zero and three functional pairs of inhibitory KIRs

and HLAs (zero: $n = 7$; one: $n = 23$; two: $n = 43$; three: $n = 3$; Fig. 2C and D); none of which was associated with clinical outcome.

Selected KIR alleles are positively associated with MR^{4.0} achievement

We next investigated whether allelic polymorphisms of KIR genes were associated with achievement of MR^{4.0}. Because four KIR genes *KIR2DL4*, *KIR2DS4*, *KIR3DL1*, and *KIR3DL2* have abundant allelic polymorphisms (Table 2), the relationships of these alleles with disease outcome were investigated. The presence of several KIR alleles was positively correlated with the achievement of MR^{4.0} in univariate analysis (Table 3 and Fig. 3), which included *KIR2DL4**005/011, *KIR2DL4**008, *KIR2DS4**003, *KIR2DS4**007/010, *KIR3DL1**005, *KIR3DL2**009, and *KIR3DL2**010 (*KIR2DL4**005/011 or *008: HR = 1.942, 95% CI = 1.160–3.250, $P = 0.012$; *KIR2DS4**003 or *007/010: HR = 3.878, 95% CI = 2.125–7.075, $P < 0.001$; *KIR3DL1**005: HR = 3.634, 95% CI = 1.884–7.013, $P < 0.001$; *KIR3DL2**010 or *009: HR = 1.864, 95% CI = 1.067–3.258, $P = 0.029$; Table 3). Even after adjustment for the two prognostic factors, second-generation TKIs as first-line therapy and patient sex (female), these alleles remained significantly correlated with achievement of MR^{4.0} (*KIR2DL4**011/005 or *008: HR = 1.797, 95% CI = 1.052–3.067, $P = 0.032$; *KIR2DS4**003 or *007/010: HR = 3.348, 95% CI = 1.773–6.323, $P < 0.001$; *KIR3DL1**005: HR = 2.746, 95% CI = 1.403–5.376, $P = 0.003$; *KIR3DL2**009 or *010: HR = 1.980, 95% CI = 1.109–3.524, $P = 0.021$; Table 3). Estimation of *KIR2DL4*–*3DL1/3DS1*–*2DS4*–*3DL2* haplotypes at the allele level suggested that *KIR3DL1**005 and several other favorable alleles were linked (Supplementary Table S1). As shown in haplotypes #8, #9, #14, and #15 (Supplementary Table S1), alleles *KIR2DL4**005/011, *KIR2DS4**003, *KIR2DS4**007/010, and *KIR3DL2**009/010 were present in several KIR haplotypes that had *KIR3DL1**005 in common, which were associated with improved therapeutic effects of TKIs (Table 3 and Fig. 3). These results

**Figure 2.**

Cumulative incidences of MR^{4.0} according to *KIR* haplotypes and activating and inhibitory KIRs. **A**, Cumulative incidences of MR^{4.0} (%MR^{4.0}) over time are presented according to different *KIR* haplotypes. Solid line, patients homozygous for *KIR* haplotype A (A/A); dashed line, B/x haplotypes (A/B and B/B; $P = 0.214$). **B**, %MR^{4.0} are presented according to the presence or absence of functional combinations of activating *KIR* and *HLA* genes. Solid line, patients with activating *KIR*s and their ligands; dashed line, patients without those combinations ($P = 0.918$). **C** and **D**, %MR^{4.0} are presented according to the number of combinations of inhibitory *KIR*s and their ligands. **C**, Black solid line, patients without any combinations; black dashed line, one combination; gray solid line, two combinations; gray dashed line, three combinations ($P = 0.368$). **D**, Patients were divided into highly licensed (number of combinations of inhibitory *KIR*s and their ligands: two or three) and poorly licensed (zero or one). Solid line, highly licensed patients; dashed line, poorly licensed patients ($P = 0.818$). All curve comparisons were completed using log-rank tests for time to achievement of MR^{4.0}, and $P < 0.05$ were considered statistically significant. Number of patient indicated in **A–D**.

provide evidence that the *KIR3DL1*005* allele, in particular, may be associated with superior prognosis, and, therefore, we next focused on the impact of allelic polymorphisms of *KIR3DL1* and its ligand *HLA-B*.

Interaction avidity between *KIR3DL1* and *HLA-B* contributes to TKI responses

*KIR*s encoded by *KIR3DL1* alleles were classified into high (*KIR3DL1-h*), low (*KIR3DL1-l*), and null (*KIR3DL1-n*) subtypes based on protein expression levels and sequence homology (refs. 17, 29, 30; Supplementary Table S2). *KIR3DL1*015* and **001* belonged to the *KIR3DL1-h* isoform, and *KIR3DL1*005* and **007* to the *KIR3DL1-l* isoform. Although *HLA-B* genotypes were segregated into Bw4 and Bw6 subtypes, only the former can act as a ligand of *KIR3DL1*. *HLA-Bw4* is dimorphic at position 80 (isoleucine (80I) or threonine (80T); ref. 36; Supplementary Table S2). *KIR3DL1* and *Bw4/6* polymorphisms defined *KIR3DL1-H/L/N* subtypes and *Bw4/6* subtypes, respectively (Supplementary Table S3), and their combination defined three subgroups based on the biological avidity of the interaction between their respective proteins (refs. 31, 33, 36; Supplementary Table S4). *KIR/HLA* combinations with high avidity were recognized as strongly interacting *KIR/HLA* combinations, which included *KIR3DL1-H/Bw4-80I* and *KIR3DL1-L/Bw4-80T*. *KIR/HLA* combinations with low avidity were recognized as weakly interacting combinations, which included *KIR3DL1-H/Bw4-80T* and *KIR3DL1-L/Bw4-80I*. *KIR/HLA* combinations without avidity were recognized as noninteracting combinations, which included *KIR3DL1-N/HLA-B* and *KIR3DL1/Bw6*.

We analyzed associations of the *KIR/HLA* combinations with clinical outcome. The analyses distributed 35 (46.1%) patients to strong interactors, 29 (38.2%) patients to weak interactors, and 12 (15.8%) patients to noninteractors. Noninteractors were more likely to achieve MR^{4.0} than strong interactors (HR = 2.208, 95% CI = 1.034–4.713, $P = 0.041$; Fig. 3E). Among weak interactors, carriers of *KIR3DL1*005* (11 of 29 patients) had better outcomes than those without this allele (HR = 14.22, 95% CI = 3.648–55.44, $P < 0.001$; Fig. 3F).

NK cell degranulation is associated with MR^{4.0} and patient sex


K562 is a human erythromyeloblastoid leukemia cell line that lacks *HLA* class I expression. These cells activate NK cells, resulting in IFN γ secretion and degranulation. We investigated whether the magnitude of NK cell activation *in vitro* was associated with achievement of MR^{4.0} by analyzing patient PBMC samples. Patients who achieved MR^{4.0} exhibited higher CD107a, a marker for degranulation (Fig. 4A and B), and their levels of IFN γ release also tended to be higher (Fig. 4A and C). Higher CD107a and IFN γ release was also observed in female patients compared with male patients (Fig. 4D and E). These results suggest that achievement of deep molecular response in CML patients depended on NK cell activation.

Discussion

Our findings demonstrated that first-line treatment with second-generation TKIs and patient sex, specifically female, were associated with the achievement of MR^{4.0}, consistent with

Figure 3.

Cumulative incidences of MR^{4.0} achievement according to selected *KIR* alleles and combinations of *KIR3DL1* and HLA-B alleles. Cumulative incidences of MR^{4.0} are shown segregated according to the presence or absence of (A) *KIR2DL4**005/011 or *008; (B) *KIR2DS4**003 or 007/010 (C) *KIR3DL1**005; and (D) *KIR3DL2**009 or *010. E and F, To investigate associations with the avidity of interactions between *KIR3DL1* and HLA-B and patient outcome, patients were classified into three subgroups based on *KIR3DL1* alleles and HLA-B subtypes: strong interactors (*n* = 35, black dashed line), weak interactors (*n* = 29, gray solid line), and noninteractors (*n* = 12, black solid line). E, Cumulative incidences of MR^{4.0} are shown for the three subgroups. Noninteractors exhibited higher levels of MR^{4.0} achievement compared with strong interactors (*P* = 0.039). F, Cumulative incidences of MR^{4.0} are shown for weak interactors, further segregated depending on the presence of *KIR3DL1**005 using log-rank test, and *P* < 0.05 were considered statistically significant; *P* < 0.001. Number of patient indicated in A-F.



previous reports (44, 45). Second-generation TKIs inhibit BCR-ABL and induce apoptosis of CML cells over 100 times more potently than imatinib (46), resulting in early and deep molecular remission in patients with CML. Of our patients, 82.5% achieved MR^{3.0} and 48% achieved MR^{4.0}, consistent with previous reports that dasatinib achieved MR^{3.0} in 85% and MR^{4.0} in 42% of Japanese CML patients after 2 years (47). Female CML patients are reported to achieve early and deep molecular responses (45), and to sustain TFR, also consistent with our results. Together, these findings indicate that our patient group was representative and supportive of previously generated data.

Although early molecular response (*BCR-ABL* ≤ 10% at 3 months) is now recognized as an important favorable prognostic factor in TKI-treated CML, Sokal scores do not always predict outcome, especially because of the advent of TKIs (48). Our analysis indicated that patients with high Sokal scores achieve MR^{4.0} more frequently than those with intermediate or low scores. However, because only ten patients were assigned high Sokal scores, we cannot conclude that high Sokal score is inversely correlated with outcome, and we do not think that our results are sufficient to contradict the previous consensus. Further investigation is needed to elucidate the association between Sokal score and treatment response in the second-generation TKI era.

Higher CD107a degranulation of NK cells was observed in female patients and those who achieved MR^{4.0}, implying that the magnitude of NK cell activation may contribute to the efficacy of TKIs. We found that several alleles, *KIR2DL4*, *KIR3DL1*, and *KIR2DS4*, were associated with achievement of MR^{4.0}, and all three of these *KIR*s contributed to haplotype A. Specifically, we identified favorable subpopulations carrying specific *KIR* alleles among CML patients with KIR haplotype A. Previous reports indicate that homozygosity for KIR haplotype A correlates with superior molecular response (27). Our analysis did not directly support these observations, which may be due to the different *KIR* allele frequencies among Caucasian and Japanese populations (33). Compared with Caucasians, the frequency of functional *KIR2DL4* and *KIR2DS4* alleles in the Japanese population is much higher (33), and therefore, in Japanese patients, KIR haplotype A may be more suppressive, resulting in less NK cell cytotoxicity and antitumor immunity than in Caucasians.

*KIR3DL1**005 was strongly associated with specific alleles of three other *KIR* genes: *KIR2DL4*, *KIR2DS4*, and *KIR3DL2*. We identified several known *KIR* allelic haplotypes, such as *KIR2DL4**005/011-*KIR2DS4**007/010-*KIR3DL2**010, *KIR2DL4**005/011-*KIR2DS4**007/010-*KIR3DL2**002, and *KIR2DL4**005/011-*KIR2DS4**007/010-*KIR3DL2**009, representing recognized haplotypes that have




Figure 4.

Activation status of NK cells is associated with therapeutic effects of TKIs. PBMCs from CML patients were cocultured with HLA class I-deficient K562 cells for 6 hours, and CD107a degranulation and intracellular IFN γ release from NK cells were analyzed by flow cytometry (E:T ratio 10:1). Representative plots from (A) patients who did and did not achieve MR $^{4.0}$ are shown and (B and C) aggregated results are also plotted. Achieved MR $^{4.0}$: $n = 46$; did not achieve MR $^{4.0}$: $n = 11$. D and E, Data from patients segregated into male ($n = 34$) and female ($n = 23$) are also presented. Statistical comparisons were made using the Mann-Whitney test, and $P < 0.05$ were considered statistically significant.

the *KIR3DL1*005* allele in common (33). These haplotypes could affect therapeutic responses to TKIs by generating increased NK cell activity, which suggests the particular significance of the *KIR3DL1*005* allele. Of these KIRs, polymorphism of *KIR3DL1* has been most investigated, demonstrating differential expression and functions for each allele at this locus (29, 31, 33, 49). Some reports have indicated clinical impacts of allelic polymorphisms in *KIR3DL1* in HIV infection (36), acute myelogenous leukemia relapse after hematopoietic stem cell transplantation (38, 50), and the therapeutic effects of anti-GD2 against neuroblastoma (37). Given that *KIR3DL1*005* is associated with low expression levels and a low suppressive capacity of NK cells (33, 36), this allele may be associated with more potent antitumor NK cell immunity against CML.

Both *KIR3DL1* and *HLA-B* exhibit allelic polymorphisms. *KIR3DL1* alleles are divided into three subtypes (*KIR3DL1-H/L/N*), as are those of *HLA-B* (Bw4-80T, Bw4-80I, and Bw6; refs. 29, 31). It is assumed that combinations of *KIR3DL1* and *HLA-B* alleles define the differential avidity of interactions between them, which may determine the potency of NK cell immunity (21, 51). Weakly interactive combinations of *KIR3DL1* and *HLA-B* hardly suppress NK cell cytotoxicity, resulting in higher NK cell activation and superior therapeutic effects of anti-GD2 antibody (37). In our study, noninteracting combinations and weakly interacting combinations involving

*KIR3DL1*005* were associated with improved achievement of MR $^{4.0}$. These results are in accordance with previous reports relating to anti-GD2-treated neuroblastoma and acute myelogenous leukemia after allo-HSCT (37, 38). However, this report indicated a clinical impact of *KIR3DL1/HLA-B* interactions in TKI-treated CML. Allelic polymorphisms of *KIR2DL4/2DS4/3DL2* also exhibited statistically significant associations. We cannot comment regarding their biological impact on NK cell immunity or CML at present, as it is unclear whether these polymorphisms are associated with immunological function. However, these results warrant further investigation.

Our results from NGS of *KIR2DL4*, *KIR3DL1*, *KIR2DS4*, and *KIR3DL2* demonstrated that specific *KIR* alleles are associated with superior therapeutic effects of TKIs in CML. *KIR3DL1*005* exhibited strong linkage with *KIR2DL4*011/005* and *2DS4*007*, indicating that these alleles compose favorable *KIR* haplotypes. These results suggest that allelic genotyping of *KIRs* may enable prediction of treatment responses in TKI-treated CML patients and allow identification of patients likely to exhibit unfavorable responses who may require salvage therapy. Because MR $^{4.0}$ is essential to achieve TFR, allelic genotyping of *KIRs* may enable successful withdrawal of TKIs, although TFR was not evaluated in this study. Such an approach would contribute to reducing the cost of safe treatment for CML. These data reveal new aspects of CML through analysis of NK cell antitumor immunity.

Disclosure of Potential Conflicts of Interest

S. Kimura reports receiving commercial research grants and speakers bureau honoraria from Bristol-Myers Squibb, Novartis Pharmaceuticals, and Pfizer. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: T. Shindo, H. Tanaka, H. Saji, S. Kimura

Development of methodology: H. Saji, A. Kawaguchi, S. Kimura

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): H. Ureshino, T. Shindo, Y. Kusunoki, H. Tanaka, H. Saji

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): H. Ureshino, T. Shindo, H. Kojima, Y. Kusunoki, Y. Miyazaki, H. Tanaka, H. Saji, A. Kawaguchi

Writing, review, and/or revision of the manuscript: H. Ureshino, T. Shindo, H. Tanaka, H. Saji, A. Kawaguchi, S. Kimura

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): H. Tanaka, H. Saji, S. Kimura
Study supervision: H. Tanaka, H. Saji

Acknowledgments

This work was supported by research grants from JSPS KAKENHI (17K09908 to S. Kimura) and Bristol-Myers Squibb (to S. Kimura).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 27, 2017; revised January 27, 2018; accepted April 20, 2018; published first April 25, 2018.

References

- Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. *Am J Hematol* 2016;91:252–65.
- Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukaemia. *Nature* 2005;435:1267–70.
- Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. *Blood* 2011;118:1622–31.
- Rea D. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. *Ann Hematol* 2015;94:S149–58.
- Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. *Cancer* 2012;118:3123–7.
- Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. *Blood* 2007;109:58–60.
- Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. *Lancet Haematol* 2015;2:e528–35.
- Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. *J Clin Oncol* 2017;35:298–305.
- Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. *Lancet Oncol* 2010;11:1029–35.
- Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Götz M, et al. Dasatinib inhibits the proliferation and function of CD4 + CD25 + regulatory T cells. *Br J Haematol* 2009;144:195–205.
- Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vähä-Koskela M, et al. Dasatinib changes immune cell profiles concomitant with reduced tumor growth in several murine solid tumor models. *Cancer Immunol Res* 2017;5:157–69.
- Müller MC, Gattermann N, Lahaye T, Deininger MWN, Berndt A, Fruehauf S, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. *Leukemia* 2003;17:2392–400.
- Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi I, Tauchi T, Kimura Y, et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. *Cancer Sci* 2013;104:1146–53.
- Mustjoki S, Eklblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. *Leukemia* 2009;23:1398–405.
- Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. *Oncogene* 2008;27:5932–43.
- Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. *Immunity* 1997;7:739–51.
- Parham P. MHC class I molecules and KIRs in human history, health and survival. *Nat Rev Immunol* 2005;5:201–14.
- Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. *Immunology* 2011;132:315–25.
- Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. *Immunology* 2010;129:8–19.
- Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song Y-J, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. *Nature* 2005;436:709–13.
- Saunders PM, Pymm P, Pietra G, Hughes VA, Hitchen C, O'Connor GM, et al. Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition. *J Exp Med* 2016;213:791–807.
- Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. *Nat Rev Immunol* 2013;13:133–44.
- Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. *Blood* 2014;123:678–86.
- Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. *Blood* 2009;113:726–32.
- Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, et al. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. *Blood* 2016;128:297–312.
- Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. *Leukemia* 2012;26:296–302.
- La Nasa G, Caocci G, Littera R, Atzeni S, Vacca A, Mulas O, et al. Homozygosity for killer immunoglobulin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. *Exp Hematol* 2013;41:424–31.
- Norman PJ, Hollenbach JA, Nemat-Gorgani N, Marin WM, Norberg SJ, Ashouri E, et al. Defining KIR and HLA class I genotypes at highest resolution via high-throughput sequencing. *Am J Hum Genet* 2016;99:375–91.
- Thomas R, Yamada E, Alter G, Martin MP, Bashirova AA, Norman PJ, et al. Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? *J Immunol* 2008;180:6743–50.
- Boudreau JE, Le Ludeuc J-B, Hsu KC. Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles. *PLoS One* 2014;9:e99543.

Ureshino et al.

31. Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. *J Immunol* 2005;175:5222–9.
32. Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. *J Exp Med* 2005;201:1069–75.
33. Yawata M, Yawata N, Draghi M, Little A-M, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. *J Exp Med* 2006;203:633–45.
34. O'Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. *J Immunol* 2007;178:235–41.
35. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. *J Exp Med* 1994;180:1235–42.
36. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. *Nat Genet* 2007;39:733–40.
37. Forlenza CJ, Boudreau JE, Zheng J, Ludeuc JB Le, Chamberlain E, Heller G, et al. KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to Anti-GD2 monoclonal antibody in patients with neuroblastoma. *J Clin Oncol* 2016;34:2443–51.
38. Boudreau JE, Giglio F, Cooley TA, Stevenson PA, Le Ludeuc J-B, Shaffer BC, et al. KIR3DL1/HLA A-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation. *J Clin Oncol* 2017;35:2268–78.
39. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016;127:2391–405.
40. Nelson WC, Pyo C-W, Vogan D, Wang R, Pyon Y-S, Hennessey C, et al. An integrated genotyping approach for HLA and other complex genetic systems. *Hum Immunol* 2015;76:928–38.
41. Bryceson YT, March ME, Barber DF, Ljunggren H-G, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. *J Exp Med* 2005;202:1001–12.
42. Rajagopalan S, Long EO. Understanding how combinations of HLA and KIR genes influence disease. *J Exp Med* 2005;201:1025–9.
43. Tanimine N, Ohdan H. Impact of multiplicity of functional KIR-HLA compound genotypes on hepatocellular carcinoma. *Oncoimmunology* 2015;4:e983765.
44. Kantarjian H, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). *Blood* 2012;119:1123–9.
45. Breccia M, Colafigli G, Molica M, De Angelis F, Quattrocchi L, Latagliata R, et al. Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib. *Br J Haematol* 2016;173:945–6.
46. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. *Clin Cancer Res* 2005;11:4941–7.
47. Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, et al. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. *Int J Hematol* 2014;99:141–53.
48. Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. *Blood* 2014;124:511–8.
49. Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH, Rajalingam R, et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. *J Immunol* 2001;166:2992–3001.
50. Marra J, Greene J, Hwang J, Du J, Damon L, Martin T, et al. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia. *J Immunol* 2015;194:4222–30.
51. Draghi M, Yawata N, Gleimer M, Yawata M, Valiante NM, Parham P. Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I. *Blood* 2005;105:2028–35.

Cancer Immunology Research

Allelic Polymorphisms of *KIRs* and *HLAs* Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML

Hiroshi Ureshino, Takero Shindo, Hiroto Kojima, et al.

Cancer Immunol Res 2018;6:745-754. Published OnlineFirst April 25, 2018.

Updated version Access the most recent version of this article at:
doi:[10.1158/2326-6066.CIR-17-0462](https://doi.org/10.1158/2326-6066.CIR-17-0462)

Supplementary Material Access the most recent supplemental material at:
<http://cancerimmunolres.aacrjournals.org/content/suppl/2018/04/25/2326-6066.CIR-17-0462.DC1>

Cited articles This article cites 51 articles, 23 of which you can access for free at:
<http://cancerimmunolres.aacrjournals.org/content/6/6/745.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerimmunolres.aacrjournals.org/content/6/6/745>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.